Efficacy and safety of different doses of subcutaneous galcanezumab in chronic and episodic migraine: A pooled analysis of 3651 patients

被引：0
|
作者：
Zaazouee, Mohamed Sayed [1 ]
Elsnhory, Ahmed [2 ]
Ebrahim, Rokaya Y. [3 ]
Al-araj, Ghaida'a [4 ]
Saad, Ahmed [5 ]
Zaki, Ibram [6 ]
Ali, Mustafa Hussein [7 ]
Fawy, Omar Khaled Fahmy [8 ]
Ahmed, Hadi F. [9 ]
Elshennawy, Mohamed [1 ]
Eleyan, Mohammed [10 ]
Alahmad, Ziad [11 ]
Hamra, Reem I. Abo [12 ]
AbuEl-Enien, Hazem [13 ]
Elromely, Rasha Abdo [14 ]
Elshanbary, Alaa Ahmed [14 ]
机构：
[1] Al Azhar Univ, Fac Med, Assiut, Egypt
[2] Al Azhar Univ, Fac Med, Cairo, Egypt
[3] Alexandria Univ, Dept Biotechnol, Fac Sci, Alexandria, Egypt
[4] Al Balqa Appl Univ, Fac Med, Salt, Jordan
[5] Menoufia Univ, Fac Med, Menoufia, Egypt
[6] Beni Suef Univ, Fac Med, Bani Suwayf, Egypt
[7] Al Taff Univ Coll, Dept Anesthesia Tech & Intens care, Karbala, Iraq
[8] Helwan Univ, Fac Med, Helwan, Egypt
[9] Red Sea Univ, Fac Med & Hlth Sci, Port Sudan, Sudan
[10] Al Aqsa Univ, Dept Lab Med Sci, Gaza, Palestine
[11] Univ Aleppo, Fac Med, Aleppo, Syria
[12] Al Quds Univ, Fac Med, Gaza, Palestine
[13] Pharos Univ, Fac Pharm & Drug Mfg, Alexandria, Egypt
[14] Alexandria Univ, Fac Med, Alexandria, Egypt
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000203515
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P10-12.003
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
    Michael Ament
    Kathleen Day
    Virginia L. Stauffer
    Vladimir Skljarevski
    Mallikarjuna Rettiganti
    Eric Pearlman
    Sheena K. Aurora
    The Journal of Headache and Pain, 2021, 22
  • [22] Immunogenicity findings from Phase 3 galcanezumab trials in patients with episodic or chronic migraine
    Martinez, James M.
    Garce, Sandra
    Anglin, Greg
    Hodsdon, Michael
    Kielbasa, William
    Moser, Brian A.
    Pearlman, Eric
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [23] Effect of Age on Efficacy and Safety of Galcanezumab Treatment in Adult Patients with Migraine
    Stauffer, Virginia L.
    Turner, Ira
    Kemmer, Phebe
    Port, Martha
    Day, Kathleen
    Camporeale, Angelo
    NEUROLOGY, 2019, 92 (15)
  • [24] Immunogenicity Assessment from Phase 3 Galcanezumab Trials in Patients with Episodic or Chronic Migraine
    Martinez, James M.
    Hindiyeh, Nada
    Anglin, Greg
    Kalidas, Kavita
    Hodsdon, Michael E.
    Kielbasa, William
    Moser, Brian A.
    Pearlman, Eric
    Garces, Sandra
    NEUROLOGY, 2019, 92 (15)
  • [25] Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine
    Martinez, James M.
    Hindiyeh, Nada
    Anglin, Greg
    Kalidas, Kavita
    Hodsdon, Michael E.
    Kielbasa, William
    Moser, Brian A.
    Pearlman, Eric M.
    Garces, Sandra
    CEPHALALGIA, 2020, 40 (09) : 978 - 989
  • [26] Efficacy and Safety of Galcanezumab as a Preventive Treatment for Episodic Migraine in South Korean Patients: A Post-Hoc Analysis of a Phase 3 Clinical Trial
    Kim, Byung-Kun
    Cho, Soo-Jin
    Han, Jeong Hee
    Dell'Agnello, Grazia
    Panni, Tommaso
    Kim, Manho
    Oh, Kyungmi
    Moon, Heui-Soo
    Chu, Min Kyung
    JOURNAL OF CLINICAL NEUROLOGY, 2023, 19 (05): : 483 - 494
  • [27] Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure
    Ruff, Dustin D.
    Ford, Janet H.
    Tockhorn-Heidenreich, Antje
    Sexson, Matthew
    Govindan, Sriram
    Pearlman, Eric M.
    Wang, Shuu-Jiun
    Khan, Arif
    Aurora, Sheena K.
    CEPHALALGIA, 2019, 39 (08) : 931 - 944
  • [28] Efficacy Results from an Open-Label Safety Study of Galcanezumab in Patients with Episodic or Chronic Cluster Headache
    Gaul, C.
    Riesenberg, R.
    Stroud, C.
    Dong, Y.
    Oakes, T. Myers
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 234 - 235
  • [29] BUDGET IMPACT ANALYSIS OF GALCANEZUMAB-GNLM FOR THE PREVENTIVE TREATMENT OF PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE IN THE UNITED STATES
    Foster, S. A.
    Milev, S.
    Hoog, M.
    Mason, O.
    Sardesai, A.
    Hasan, A.
    Marrone, C.
    VALUE IN HEALTH, 2019, 22 : S277 - S277
  • [30] Efficacy Results from an Open-Label Safety Study of Galcanezumab in Patients with Episodic or Chronic Cluster Headache
    Gaul, C.
    Riesenberg, R.
    Stroud, C.
    Dong, Y.
    Oakes, T. Myers
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 2):
12345